Rectal Cancer Clinical Trial
Official title:
The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer
Rationale and background: Predictive factors are needed to discriminate chemoradiotherapy
responders from non-responders and to individualize the treatment regime. Various cytokines
play a role in processes affecting tumour growth and metastasis. Furthermore, cytokines
might influence treatment response. Various cytokines are abnormally expressed in colorectal
cancer patients, are associated with colorectal cancer or determine response to
chemoradiotherapy. Therefore the investigators want to investigate whether levels of
circulating cytokines could predict response to preoperative chemoradiotherapy in patients
with rectal cancer.
Hypothesis: The investigators hypothesis is that the varying levels of circulating cytokines
in the blood of rectal cancer patients may predict the response to preoperative
chemoradiotherapy.
Study design: This study is an explorative clinical pilot study in which the investigators
will collect 4 ml of blood from a selection of rectal cancer patients during a regular
venipuncture before, during and after preoperative chemoradiotherapy and before and after
surgery. Cytokines will be measured in blood plasma and in tumour and healthy tissue from
the resection specimen using multiplex immunoassays. Plasma cytokine measurements will be
linked to pathological response to identify which cytokines and corresponding levels can
predict response to preoperative chemoradiotherapy for patients with locally advanced rectal
cancer. Furthermore, blood plasma cytokine measurements before and after surgery will be
compared to evaluate the effect of tumour resection on the immune response. In addition,
preoperative blood plasma cytokine levels will be compared with cytokine levels in normal
and tumour tissue to test whether circulating cytokine levels are representative for tissue
cytokine levels.
Study population: Thirty patients (≥18 years) with locally advanced rectal adenocarcinoma
eligible for preoperative chemoradiotherapy (oral capecitabine and 45-50 gray (Gy) in total;
fractions of 1.8-2 Gy) and surgery.
Country of recruitment: The Netherlands
n/a
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |